445 related articles for article (PubMed ID: 12577250)
21. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
[TBL] [Abstract][Full Text] [Related]
22. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
Jellema AP; Slotman BJ; Muller MJ; Leemans CR; Smeele LE; Hoekman K; Aaronson NK; Langendijk JA
Cancer; 2006 Aug; 107(3):544-53. PubMed ID: 16804929
[TBL] [Abstract][Full Text] [Related]
23. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
Koukourakis MI; Kyrias G; Kakolyris S; Kouroussis C; Frangiadaki C; Giatromanolaki A; Retalis G; Georgoulias V
J Clin Oncol; 2000 Jun; 18(11):2226-33. PubMed ID: 10829042
[TBL] [Abstract][Full Text] [Related]
24. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
[TBL] [Abstract][Full Text] [Related]
25. Moist skin care can diminish acute radiation-induced skin toxicity.
Momm F; Weissenberger C; Bartelt S; Henke M
Strahlenther Onkol; 2003 Oct; 179(10):708-12. PubMed ID: 14566480
[TBL] [Abstract][Full Text] [Related]
26. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
27. Amifostine--a radioprotector in locally advanced head and neck tumors.
Schönekäs KG; Wagner W; Prott FJ
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():27-9. PubMed ID: 10584137
[TBL] [Abstract][Full Text] [Related]
28. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
[TBL] [Abstract][Full Text] [Related]
29. Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.
Büntzel J; Glatzel M; Mücke R; Micke O; Bruns F
Anticancer Res; 2007; 27(4A):1953-6. PubMed ID: 17649803
[TBL] [Abstract][Full Text] [Related]
30. A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer.
Anné PR; Machtay M; Rosenthal DI; Brizel DM; Morrison WH; Irwin DH; Chougule PB; Estopinal NC; Berson A; Curran WJ
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):445-52. PubMed ID: 17141978
[TBL] [Abstract][Full Text] [Related]
31. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine.
Braaksma M; van Agthoven M; Nijdam W; Uyl-de Groot C; Levendag P
Eur J Cancer; 2005 Sep; 41(14):2102-11. PubMed ID: 16140526
[TBL] [Abstract][Full Text] [Related]
32. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
33. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
[No Abstract] [Full Text] [Related]
34. [Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].
Huang R; Yu H; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2002 Dec; 19(4):708-11. PubMed ID: 12561384
[TBL] [Abstract][Full Text] [Related]
35. Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers.
Anacak Y; Kamer S; Haydaroglu A
Pediatr Blood Cancer; 2007 May; 48(5):579-81. PubMed ID: 16395679
[TBL] [Abstract][Full Text] [Related]
36. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
de Castro G; Federico MH
Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
[TBL] [Abstract][Full Text] [Related]
37. The use of amifostine to prevent xerostomia in patients receiving radiation therapy.
Batcha M
Oncol Nurs Forum; 2000 May; 27(4):615-6. PubMed ID: 10833684
[No Abstract] [Full Text] [Related]
38. Established and emerging uses of cytoprotection in head and neck cancer.
Rosenthal DI
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):129-30. PubMed ID: 16490868
[No Abstract] [Full Text] [Related]
39. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]